Davita’s (DVA) Buy Rating Reaffirmed at Bank of America

Davita (NYSE:DVA)‘s stock had its “buy” rating reiterated by research analysts at Bank of America in a research report issued on Thursday. They presently have a $92.00 price objective on the stock, up from their previous price objective of $85.00. Bank of America’s price target points to a potential upside of 17.84% from the stock’s current price.

A number of other research firms also recently weighed in on DVA. TheStreet upgraded Davita from a “c” rating to a “b-” rating in a research report on Thursday, January 4th. Zacks Investment Research upgraded Davita from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. SunTrust Banks set a $75.00 target price on Davita and gave the stock a “hold” rating in a research report on Thursday, December 21st. Robert W. Baird upgraded Davita from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $63.00 to $82.00 in a research report on Tuesday, December 12th. Finally, JPMorgan Chase & Co. boosted their target price on Davita from $4.90 to $84.00 and gave the stock a “strong-buy” rating in a research report on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $76.78.

Shares of Davita (NYSE:DVA) opened at $78.07 on Thursday. The firm has a market capitalization of $14,310.00, a price-to-earnings ratio of 29.91, a PEG ratio of 15.06 and a beta of 0.96. Davita has a 52-week low of $52.51 and a 52-week high of $78.12. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40.

Davita (NYSE:DVA) last released its earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.13). The firm had revenue of $3.92 billion for the quarter, compared to the consensus estimate of $3.91 billion. Davita had a return on equity of 13.31% and a net margin of 3.40%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.95 EPS. research analysts forecast that Davita will post 3.42 EPS for the current year.

Davita announced that its Board of Directors has approved a share repurchase program on Tuesday, October 10th that authorizes the company to buyback $1.50 billion in shares. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

In related news, VP Leanne M. Zumwalt sold 949 shares of Davita stock in a transaction on Friday, December 8th. The stock was sold at an average price of $68.19, for a total transaction of $64,712.31. Following the completion of the sale, the vice president now directly owns 12,423 shares of the company’s stock, valued at $847,124.37. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Charles Berg sold 7,048 shares of Davita stock in a transaction on Monday, December 11th. The stock was sold at an average price of $69.24, for a total value of $488,003.52. Following the sale, the insider now directly owns 5,359 shares of the company’s stock, valued at $371,057.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 117,937 shares of company stock valued at $8,028,379. 2.00% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in DVA. Schroder Investment Management Group grew its stake in shares of Davita by 53.9% during the second quarter. Schroder Investment Management Group now owns 49,967 shares of the company’s stock worth $3,201,000 after purchasing an additional 17,497 shares during the period. Accident Compensation Corp grew its stake in Davita by 147.5% in the second quarter. Accident Compensation Corp now owns 15,100 shares of the company’s stock valued at $978,000 after acquiring an additional 9,000 shares during the period. Cibc World Markets Corp grew its stake in Davita by 35.3% in the second quarter. Cibc World Markets Corp now owns 22,006 shares of the company’s stock valued at $1,425,000 after acquiring an additional 5,746 shares during the period. Flinton Capital Management LLC grew its stake in Davita by 10.7% in the second quarter. Flinton Capital Management LLC now owns 152,830 shares of the company’s stock valued at $9,898,000 after acquiring an additional 14,756 shares during the period. Finally, Oak Associates Ltd. OH grew its stake in Davita by 21.1% in the second quarter. Oak Associates Ltd. OH now owns 185,195 shares of the company’s stock valued at $11,993,000 after acquiring an additional 32,285 shares during the period. 87.94% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/11/davitas-dva-buy-rating-reaffirmed-at-bank-of-america.html.

About Davita

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply